Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Failure to Obtain Advice of a Third Party Is Not Evidence of Willfulness - In Provisur Technologies, Inc., v. Weber, Inc., ...
AFib is the most common type of heart arrythmia 2. Left untreated, it increases risk of stroke, heart failure, myocardial ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Garner, MD, Medical Director at SimpleFixRx to review it all for accuracy ... Examples include exenatide and lixisenatide.
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback